Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Semin Cancer Biol. 2017 Aug 2;51:170–179. doi: 10.1016/j.semcancer.2017.07.009

Figure 1.

Figure 1

Mutation frequency in epigenetic regulators in low-risk (refractory anemia (RA), refractory anemia with multilineage dysplasia (RCMD), and RCMD with ringsideroblasts (RCMD-RS) and high-risk (refractory anemia with excess of blasts (RAEB-1 and RAEB2)) WHO categories of MDS patients including mutations of oncogenic, possibly oncogenic as well as of unknown oncogenic potential. The data is based on a publication by Papaemmanuil et al. using mutation information in Supplementary Table S2.2 * indicates P<0.01.